

Alert	Data in neonates are limited. Use in neonates should be restricted and considered experimental. Further studies are needed.
Indication	Persistent Pulmonary Hypertension of the Neonate (PPHN): <ul style="list-style-type: none"> - refractory to inhaled nitric oxide (iNO) and other conventional therapies or - those who are persistently unable to be weaned off inhaled nitric oxide or - in situations where inhaled nitric oxide and high frequency ventilation are not available Chronic pulmonary hypertension secondary to respiratory, cardiac or chest wall disease.
Action	Selective phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is found in the smooth muscle of the pulmonary vasculature, where it is responsible for the degradation of cyclic guanosine monophosphate (cGMP). cGMP produces smooth muscle relaxation. Sildenafil increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to selective vasodilatation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation.
Drug Type	Phosphodiesterase type 5 (PDE5) inhibitor.
Trade Name	IV: Revatio Oral: Pharmacy prepared
Presentation	IV: Vial for injection containing 10 mg/12.5 mL = 0.8 mg/mL of sildenafil Oral: Pharmacy-prepared oral suspension
Dosage/Interval	IV: Loading: 0.4 mg/kg administered over THREE hours followed by: Maintenance: 1.6 mg/kg/day (0.067 mg/kg/hour) as a continuous infusion for up to 7 days. PO: Start at 0.5 to 1 mg/kg/dose given 6 to 8 hourly and titrate up to 2 mg/kg/dose according to response. May increase up to maximum of 3 mg/kg/dose given 6 hourly. To avoid the possible occurrence of sudden clinical deterioration during withdrawal of sildenafil, a gradual dose reduction should be considered when stopping sildenafil.
Route	IV, oral
Preparation/Dilution	See below
Administration	IV infusion: Low concentration IV infusion (weight > 2.5 kg) Draw up 2.5mL/kg (2 mg/kg of sildenafil) solution and make up to 15 mL using glucose 5% (preferred) or sodium chloride 0.9%. Infuse 1 mL/h for 3 hours (loading dose of 0.4 mg/kg) followed by 0.5 mL/h (0.067 mg/kg/h) High concentration IV Infusion (weight ≤ 2.5 kg) Draw up 4.2mL/kg (3.36 mg /kg of sildenafil) solution and make up to 15 mL using glucose 5% (preferred) or sodium chloride 0.9%. Infuse 0.6 mL/h for 3 hours (loading dose of 0.4 mg/kg) followed by 0.3 mL/h (0.067 mg/kg/h) Oral: Shake well before drawing up the dose. Give via intragastric tube, preferably with feed to minimise risk of gastrointestinal irritation. If baby is not on enteral feeds or breast milk is not available, give dose via intragastric tube and flush with 0.5 mL water for injection.
Monitoring	Heart rate, blood pressure and oxygenation. Renal and hepatic function. Consider monitoring with echocardiogram.
Contraindications	Hypersensitivity to sildenafil Not to be used in patients taking organic nitrates of any form e.g. glyceryl trinitrate, isosorbide mononitrate, sodium nitroprusside

Precautions	Use with caution in neonates with sepsis or uncontrolled hypotension. Sildenafil clearance (in adults) is reduced in hepatic and severe renal impairment.
Drug Interactions	Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. Thus, erythromycin and fluconazole may increase concentrations of sildenafil by reducing hepatic clearance and rifampicin may decrease concentrations by inducing its hepatic metabolism. Avoid concomitant use of sildenafil with: Alprostadil (prostaglandin E1), other antihypertensives and vasodilators, as they may have their effects potentiated by sildenafil.
Adverse Reactions	Most concerning short-term adverse effects: Worsening oxygenation and systemic hypotension. Epistaxis, respiratory symptoms (cough and nasal congestion), diarrhoea and vomiting, gastroesophageal reflux and abdominal pain, headaches, tremors, erections, facial flushing, dizziness, irritability and (rarely) fever, skin disorders, pain in limbs and oedema have been reported in children on sildenafil. The Sildenafil in Treatment-Naïve Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension long-term extension (STARTS-2) trial showed worse survival in children receiving high doses of sildenafil as monotherapy. ² A recent study conducted by Roldan and colleagues, found there was a statistically significant increase in adverse drug reaction (ADR) frequency in children receiving higher-than-recommended doses. However, it was not associated with a lower survival rate. ¹⁴ Sildenafil has the potential to adversely affect vision. ¹³ Impaired liver function tests. May increase the risk of severe retinopathy of prematurity if used in extremely preterm neonates.
Compatibility	Glucose 5%, sodium chloride 0.9%.
Incompatibility	No data – where possible administer via dedicated line.
Stability	IV – infusion should be changed every 24 hours. Oral suspension – as per pharmacy advice.
Storage	IV – unopened vials at room temperature (20–25°C). Oral suspension – refrigerate, do not freeze
Special Comments	In paediatric patients with pulmonary arterial hypertension, an increased mortality risk was associated with long-term (> 2 year) use. The mortality risk of long-term use in neonates is unknown.
Evidence summary	<p>Neonates with pulmonary hypertension</p> <p>Shah et al⁹ performed a systematic review on sildenafil compared with placebo or other pulmonary vasodilators, irrespective of dose, route and duration of administration, in neonates with PPHN. Three eligible trials that enrolled 77 infants were identified. The methodological quality of the studies indicated low-moderate risk of bias. All studies were performed in resource-limited settings where iNO and high frequency ventilation were not available at the time of study. There was a significant reduction in mortality in the sildenafil group (typical RR 0.20, 95% CI 0.07 to 0.57; typical RD -0.38, 95% CI -0.60 to -0.16; Number needed to treat to benefit 3, 95% CI 2 to 6). Physiological parameters of oxygenation (oxygenation index, PaO₂) suggested a steady improvement after the first dose of sildenafil. No clinically important side effects were identified. Sildenafil in the treatment of PPHN has significant potential especially in resource limited settings (LOEI, GOR B).</p> <p>The European Paediatric Pulmonary Vascular Disease Network’s consensus statement 2016: Oral sildenafil should be considered for treatment of PPHN and PH in BPD, especially if iNO is not available (LOE IIa GOR B). Intravenous sildenafil may be considered for treatment of PH, including PPHN, in critically ill patients, especially in those with an unsatisfactory response to iNO (LOE IIb GOR B).^{4,5}</p> <p>Paediatric pulmonary hypertension</p> <p>STARTS-1 trial performed by Barst et al,¹ studied the effectiveness of oral sildenafil in children with pulmonary arterial hypertension. 238 children with a weight ≥ 8 kg were randomised to low-, medium-, or high-dose sildenafil or placebo orally 3 times daily for 16 weeks. The primary comparison was percent change from baseline in peak oxygen consumption for the 3 sildenafil doses combined versus placebo. Percent change in PV’ O₂ for the 3 sildenafil doses combined was only marginally significant; however, PV’ O₂, functional class and haemodynamic improvements</p>

with medium and high doses suggest efficacy with these doses.

STARTS-2 was the extension of the STARTS-1 trial.² In STARTS-2, sildenafil-treated patients continued STARTS-1 dosing; placebo-treated patients were randomised to 1 of the 3 sildenafil dose groups. Patients requiring additional pulmonary arterial hypertension-specific therapy discontinued study treatment; survival follow-up was attempted. Hazard ratios for mortality were 3.95 (95% confidence interval, 1.46–10.65) for high versus low and 1.92 (95% confidence interval, 0.65–5.65) for medium versus low dose; however, multiple analyses raised uncertainty about the survival/dose relationship. In summary, although children randomised to higher compared with lower sildenafil doses had an unexplained increased mortality, all sildenafil dose groups displayed favourable survival for children with pulmonary arterial hypertension. Combined with STARTS-1 data, the overall profile favoured the medium dose.

Preterm infants at risk of BPD

Konig et al⁶ performed an RCT in preterm infants, < 28 weeks gestational age, if they were mechanically ventilated on day 7 of life. Infants were randomised to a 4-week course of either oral sildenafil (3 mg/kg/day) or placebo solution. Twenty infants were randomised, 10 received sildenafil and 10 received placebo. Sildenafil did not reduce length of invasive (median 688 versus 227 h) or non-invasive ventilation (median 1609 versus 1416 h). More infants in the sildenafil group required postnatal steroid treatment. One infant developed hypotension following sildenafil administration and was excluded after three doses. Conclusion: Sildenafil as an early treatment for preterm infants at risk of BPD is not beneficial.

Prevention of rebound pulmonary HTN after weaning iNO

Namachivayam et al⁸ performed an RCT in 30 ventilated infants and children from varying respiratory conditions including BPD (average age 0.4 y) and receiving 10 ppm iNO. They were randomised to either 0.4 mg/kg as a single oral dose of sildenafil or placebo 1 h before discontinuing iNO. Rebound occurred in 10/14 of the placebo group and 0 out of 15 in the sildenafil group. Four placebo patients couldn't be weaned off iNO, whereas all in the sildenafil group were successfully weaned (p = 0.042). A single oral dose of sildenafil may be considered for this particular scenario (LOE II, GOR C).

Pre-op oral sildenafil for children with CHD prior to cardiopulmonary bypass

Vassalos et al,¹² in a randomised trial, compared the effects of oral sildenafil (0.5 mg/kg) and placebo, administered the day before cardiac surgery, in 24 children. Postoperatively, mean pulmonary vascular resistance and oxygenation index remained unchanged, whilst oxygen delivery and bi-ventricular systolic function were significantly reduced in the sildenafil group. In this trial, pre-operative sildenafil did not affect postoperative pulmonary vascular resistance. There was, however, a negative impact on ventricular function and oxygenation. Therefore, sildenafil is not recommended for this particular indication.

Post-op sildenafil in infants after cardiac surgery

Stocker et al¹¹ performed an RCT in 16 ventilated infants early after closure of ventricular or atrioventricular septal defects. They were randomly assigned to one of two groups. Seven infants received iNO (20 ppm) first, with the addition of intravenous sildenafil (0.35 mg/kg over 20 min) after 20 min. Eight infants received sildenafil first, iNO was added after 20 min. Intravenous sildenafil augmented the pulmonary vasodilator effects of iNO in infants early after cardiac surgery. However, sildenafil produced systemic hypotension and impaired oxygenation, which was not improved by iNO. Sildenafil is not recommended for this particular indication.

The European Paediatric Pulmonary Vascular Disease Network Consensus 2016⁷: Beneficial haemodynamic effects of sildenafil have also been demonstrated in failing Fontan circulations. Sildenafil improved max. oxygen consumption (VO₂ max.) and pulmonary blood flow in patients with Fontan circulation. Another randomised, crossover study showed that sildenafil therapy improved exercise tolerance and ventilatory efficiency in Fontan patients.

Pharmacokinetics

	<p>Steinhorn et al¹⁰ performed a multicentre, open-label, dose-escalation, pilot, pharmacokinetics study of 36 near-term and term neonates with echo-confirmed idiopathic PHN or secondary PHN with MAS, RDS, sepsis or pneumonia and OI \geq 15. The study included 8 sequential “step-up” dosing groups. Most infants received a loading dose of sildenafil to bring the plasma concentration of sildenafil to a target, followed by a maintenance infusion for the remainder of the study. The duration of IV sildenafil was for at least 48 hours and up to 7 days. They found sildenafil to be well tolerated, particularly with a dosing regimen comprising a loading dose of 0.4 mg/kg delivered over 3 hours, followed by a maintenance infusion at 1.6 mg/kg/day.</p> <p>Sildenafil and retinopathy of prematurity Sildenafil is 10 x more selective for PDE5 as compared to PDE6. PDE6 is found in the retina. If used in extremely preterm neonates, sildenafil may increase the risk of severe retinopathy of prematurity. A retrospective, case-controlled study (n = 68) in neonates born before 30 weeks gestation showed sildenafil use did not increase the risk of retinopathy of prematurity.³</p>
References	<ol style="list-style-type: none"> 1. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. <i>Circulation</i>. 2012;125(2):324-34. 2. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. <i>Circulation</i> 2014;129(19):1914-23. 3. Fang AY, Guy KJ, König K. The effect of sildenafil on retinopathy of prematurity in very preterm infants. <i>J Perinatol</i>. 2013 Mar;33(3):218-21. 4. Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> 2016;102 Suppl 2:ii67-85. 5. Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> 2016;102 Suppl 2:ii49-56. 6. König K, Barfield CP, Guy KJ, Drew SM, Andersen CC. The effect of sildenafil on evolving bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled pilot study. <i>J Matern Fetal Neonatal Med</i>. 2014;27(5):439-44. 7. Kozlik-Feldmann R, Hansmann G, Bonnet D, Schranz D, Apitz C, Michel-Behnke I. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> 2016;102 Suppl 2:ii42-8. 8. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. <i>Am J Respir Crit Care Med</i> 2006;174(9):1042-7. 9. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. <i>Cochrane Database Syst Rev</i>. 2011 Aug 10;(8):CD005494. 10. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, Wessel DL. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. <i>J Pediatr</i> 2009 Dec;155(6):841-847.e1. 11. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. <i>Intensive Care Med</i>. 2003;29(11):1996-2003. 12. Vassalos A, Peng E, Young D, Walker S, Pollock J, Macarthur K, Lyall F, Danton MH. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. <i>Anaesthesia</i> 2011;66(6):472-80. 13. Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. <i>J Postgrad Med</i>. 2015 Jul-Sep;61(3):181-92. 14. Roldan T, Deiros L, Romero JA, Gutierrez-Larraya F, Herrero A, Del Cerro MJ. Safety and tolerability of targeted therapies for pulmonary hypertension in children. <i>Pediatric cardiology</i>. 2014 Mar 1;35(3):490-8.

Original version Date: 06/10/2016	Author: Neonatal Medicines Formulary Consensus Group
Current Version number: 1.1	Current Version Date: 20/02/2017
Risk Rating: Medium	Due for Review: 20/02/2020
Approval by: As per Local policy	Approval Date: